Mead Johnson Nutrition has sold its US$1.5bn debt in a three-part sale, the company said on Friday (30 October).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The offering included $500m of 3.50% notes due 2014 priced at 99.552% of the principal amount and $700m of 4.90% notes due 2019 priced at 99.649% of the principal amount.
It also included $300m of 5.90% notes due 2039 priced at 99.973% of the principal amount.
Proceeds from the offering are intended to be used to repay debt owed to a subsidiary of Bristol-Myers Squibb Company.
The sale of the notes is expected to close on or about 5 November, the company said.
